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Abstract
Pramanicin (PMC) is an antifungal agent that was previously demonstrated to exhibit antiangiogenic and anticancer
properties in a few in vitro studies. We initially screened a number of PMC analogs for their cytotoxic effects on HCT116
human colon cancer cells. PMC-A, the analog with the most potent antiproliferative effect was chosen to further interrogate
the underlying mechanism of action. PMC-A led to apoptosis through activation of caspase-9 and -3. The apoptotic nature
of cell death was confirmed by abrogation of cell death with pretreatment with specific caspase inhibitors. Stress-related
MAPKs JNK and p38 were both activated concomittantly with the intrinsic apoptotic pathway. Moreover, pharmacological
inhibition of p38 proved to attenuate the cell death induction while pretreatment with JNK inhibitor did not exhibit a
protective effect. Resistance of Bax 2/2 cells and the protective nature of caspase-9 inhibition indicate that mitochondria
play a central role in PMC-A induced apoptosis. Early post-exposure elevation of cellular Bim and Bax was followed by a
marginal Bcl-2 depletion and Bid cleavage. Further analysis revealed that Bcl-2 downregulation occurs at the mRNA level
and is critical to mediate PMC-A induced apoptosis, as ectopic Bcl-2 expression substantially spared the cells from death.
Conversely, forced expression of Bim proved to significantly increase cell death. In addition, analyses of p532/2 cells
demonstrated that Bcl-2/Bim/Bax modulation and MAPK activations take place independently of p53 expression. Taken
together, p53-independent transcriptional Bcl-2 downregulation and p38 signaling appear to be the key modulatory events
in PMC-A induced apoptosis.
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Introduction
A multitude of naturally occurring or synthesized molecules has
been screened for their therapeutic use in human or veterinary
medicine. Having long been exploited as disinfectants and
preservatives in industry, antifungal agents have not been
exceptions to this. Pramanicin (PMC) is a fungal fermentation
product belonging to a class of antifungal agents defined by a
highly functionilized polar head and an aliphatic side chain. The
previous in vitro analyses on cultured endothelial and leukemic T-
cells confirmed its therapeutic potential both as an antiangiogenic
and anticancer agent [1,2].
Prolonged exposure to in vitro effective doses of PMC was
previously shown to decrease cell viability and trigger caspase-
dependent apoptosis [2]. PMC-induced cell death was demon-
strated to be mediated by activation of both stress-related kinases
p38 mitogen-activated protein kinase (MAPK) and c-Jun N-
terminal kinase (JNK) while extracellular regulated kinase (ERK)
activity was reported to significantly decrease upon exposure to the
agent. Although a transient intracellular calcium increase was
reported to follow PMC exposure in cultured pulmonary
endothelial cells, this phenomenon was not synchronized with
either endothelial dysfunction or cell death [1].
Physical or chemical environmental stresses including radiation,
osmotic stress, and oxidative stress or cell surface receptor ligands
such as growth factors, inflammatory cytokines or death receptor
ligands may activate a kinase cascade which eventually stimulates
stress-activated MAPKs p38 and JNK. Upstream serine/threonine
kinases MAP kinase kinase kinases (MEKKs) and MAP kinase
kinases (MKKs) are responsible for activation by phosphorylation
and subsequent nuclear translocation of JNK and p38 [3]. Once
activated, JNK and p38 are known to be capable of apoptotic
modulation through activating/deactivating a series of transcrip-
tion factors.
Apoptosis is a tightly regulated cell death mechanism which is
activated in response to various intra-/extracellular stimuli such as
oxidative stress and electromagnetic radiation that damage cellular
macromolecules or signals including inflammatory cytokines and
growth factors. Apoptotic execution is assumed by a family of
cysteine proteases called caspases that are activated in a well-
defined manner [4]. While the intrinsic pathway is triggered by
apoptogenic molecule release from mitochondria, the extrinsic
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pathway is activated through ligand binding to death receptors on
the cell surface. Whether the intrinsic or extrinsic apoptotic
pathway will be in action is generally determined by the nature of
the stimulus. Independent of the pathway that was activated
initially, both the intrinsic and extrinsic pathways could be
involved to amplify the apoptotic signal in different circumstances.
Cytochrome c release from mitochondria which marks the point
of no return for intrinsic apoptotic activity is intricately regulated
by interactions among Bcl-2 family of proteins. The delicate
balance between the anti- and proapoptotic members of the family
determines the apoptotic load within the cell. Multidomain
proapoptotic Bcl-2 proteins Bax and Bak have the ability of
homo-/heterooligomerization at the outer mitochondrial mem-
brane (OMM) which causes permeabilization of the OMM and
release of apoptogenic molecules including cytochrome c into the
cytosol. While the antiapoptotic Bcl-2 proteins such as Bcl-2, Bcl-
xL, A1 and Mcl-1 keep proapoptotic Bax/Bak sequestered
preventing them from initiating OMM permeabilization, proa-
poptotic BH3 (Bcl-2 homology 3)-only proteins including Bim,
Bid, Noxa, Bad and Puma could work to neutralize the
antiapoptotic members of the family [5,6]. Although the exact
mechanisms modulating Bcl-2 proteins still remain obscure to a
large extent, the balance between relative cellular amounts and
activities of pro- and antiapoptotic Bcl-2 proteins is known to be
strictly controlled at the gene and protein levels in healthy
mammalian cells. In this regard, cellular levels of proapoptotic
BH3-only Bcl-2 proteins relative to their antiapoptotic counter-
parts is critical to set Bax/Bak free to initiate the intrinsic apoptotic
pathway.
In addition to its roles in DNA repair and cell cycle regulation,
the well-known tumor suppressor p53 has been shown to be able
to directly regulate apoptosis. So far, this regulation has been
demonstrated to occur via modulation of Bcl-2 family protein or
death receptor expressions. In addition to transcriptionally
upregulating Bax, Bid, Puma, Noxa, Bak and transmembrane
death receptors as a transcription factor, p53 was also reported to
be capable of directly activating Bax at the protein level [7–13].
Recent evidence also indicates that p53 itself may also behave as a
BH3-only proapoptotic protein to antagonize antiapoptotic Bcl-2
proteins as well as causing transrepression of antiapoptotic Bcl-2
gene transcription [14–17].
In this study, we define a mechanism for intrinsic apoptotic
pathway activation triggered by PMC-A, a potent PMC analog in
which the epoxy group on the side chain of PMC is replaced by an
alkene (Fig. 1). PMC-A mediated apoptosis through p53-indepen-
dent activation of p38 and Bcl-2 downregulation in HCT-116
human colon cancer cells. Concomitantly, Bax and Bim were both
accumulated in cells exposed to PMC-A with subsequent Bid
truncation.
Materials and Methods
Cell Culture and Treatments
Wild-type (wt), p532/2, and Bax 2/2 HCT116 human colon
cancer cells were kindly provided by Bert Vogelstein (Howard
Hughes Medical Institute, Johns Hopkins University, USA)
[18,19], cultured in McCoy’s 5A supplemented with 10% HI
FBS and 100 IU/ml penicillin/streptomycin. Cultures were
maintained at 37uC in a humidified 5% CO2 atmosphere. Ethanol
(max 0.5%, v/v) was added to all control wells/plates in each
experiment. Cells were collected, quantified in complete medium
and seeded (100000 cells/ml) in 12-well, 6-well or 60 mm culture
plates depending on the experiment. Pramanicin and analogs were
added into the culture plates 36 hours later. Pre-treatments with
inhibitors were done for 30 minutes prior to PMC-A treatment.
Reagents and Analog Synthesis
General. Proton NMR spectra were recorded in CDCl3 or
CD3OD on a Bruker AC-200 or AC-600 spectrometer and are
reported as follows: chemical shift d (ppm); number of protons,
multiplicity, coupling constant J (Hz), and assignment. Residual
protic solvents CHCl3 (d=7.26 ppm) and CH3OH (d=3.30) were
used as the internal reference. 13C NMR spectra were recorded in
CDCl3 or CD3OD at 50 MHz on a Bruker AC-200 and
150 MHz on a Bruker AC-600 spectrometer, using the central
resonance of CDCl3 (d=77.16 ppm) as the internal reference.
Infra-red spectra were recorded on a Perkin-Elmer 983G
machine. Mass spectra were obtained on a Micromass Quattro
Ultima (LC-ESI/APCI Triple Quadrupole Mass Spectrometer) at
the chemistry department, McMaster University. The following
ionization techniques were used: electron ionization (EI), and
electrospray (ES). Melting points were determined on a Reichert
hot stage apparatus. Optical rotations were recorded on a Perkin-
Elmer (241 MC Polarimeter, l=589, Na lamp).
Pramanicin (PMC) and pramanicin A (PMC-A) were prepared
as described previously [20]. Flash column chromatography was
carried out on silica gel (SILICA GEL 60). Thin layer
chromatography (TLC) was performed on pre-coated silica plates
(ALUGRAM SIL G/UV254) and visualized by UV, vanillin or
ceric ammonium nitrate solution. Aqueous solutions were
saturated unless otherwise specified. The ratio of solvents in
mixtures refers to the volumes used. All reactions were carried out
under a nitrogen or argon atmosphere in oven-dried glassware,
which was cooled under a continuous stream of nitrogen
immediately prior to use unless otherwise stated. THF was
distilled from sodium benzophenone ketyl, CH2Cl2 and toluene
from calcium hydride, and EtOAc from potassium carbonate.
Other solvents and reagents were used as supplied.
3-Tetradecanoyl-1-vinylpyrrolidin-2-one (2). Freshly dis-
tilled N-vinylpyrrolidin-2-one (1) (0.96 mL, 9 mmol) was added to
NaH (1.44 g, 36 mmol) in refluxing THF (15 mL). The mixture
was stirred for 30 min at 90uC, and then ethyl myristate (4.3 mL,
10.3 mmol) was added. After 3 h, the solution was warmed to
room temperature, quenched with saturated aqueous NH4Cl, and
extracted with ether. The extracts were dried (Na2SO4), filtered,
and concentrated. The resulting solid was dissolved in CH2Cl2,
filtered and concentrated, and purified by chromatography
(CH2Cl2/EtOAc, 1:1) to yield 2 as white crystals (3.54 g, 82%):
mp 39–40uC; IR (film) 2920, 2851 (C-H, str.), 1685, 1637 (C=O,
str.), 1459 (C=C, bend.), 1391, 861 cm21; 1H NMR (CDCl3,
200 MHz) d 7.01 (1H, dd, 3J = 9.0, 3J = 16.0, NCH=CH2), 4.46
(2H, m, NCH=CH2), 3.68 (1H, dd,
3J = 9.0, 3J = 6.0,
COCHCO), 3.54 (1H, ddd, 2J = 9.0, 3J = 8.5, 3J = 5.5, CH2N),
3.47 (1H, ddd, 2J = 9.0, 3J = 8.5, 3J = 5.7, CH2N), 3.01 (1H, m,
CH2CH2CO), 2.68 (1H, m, CH2CH2CO), 2.67 (1H, dddd,
2J = 13.8, 3J = 5.7, 3J = 8.5, 3J = 6.0, CH2CH2N), 2.12 (1H, dddd,
2J = 13.6, 3J = 8.5, 3J = 9.0, 3J = 5.5, CH2CH2N), 1.57 (2H, m,
CH2CH2CO), 1.24 (20H, m, C10H20), 0.87 (3H, t,
2J = 6.7,
CH3CH2);
13C NMR (CDCl3, 50 MHz); d 204.2 (CH2CO), 169.9
(CON), 130.0 (NCH=CH2), 94.5 (NCH=CH2), 57.3
(COCHCO), 44.0 (CH2N), 43.5 (CH2CH2CO), 32.7, 30.4, 30.2,
29.8, 24.1, 23.5 (C10H20), 20.1 (CH2CH2CH2), 14.9 (CH3); MS
(EI+) m/z= 321 (M?+), HRMS (EI) calculated for C20H35NO2
(M?+) 321.2668, found 321.2679.
3-Tetradecanoylpyrrolidin-2-one (3). Compound 2
(520 mg, 1.6 mmol) was heated at 90uC in a mixture of 95%
C2H5OH (35 mL) and concentrated HCl (0.5 mL). The reaction
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was monitored by TLC. The solution was cooled to room
temperature, dried (Na2SO4), filtered, and concentrated. The
resulting solid was purified by chromatography (CH2Cl2/EtOAc,
1:1) to yield 3 as white crystals (241 mg, 50.4%): mp 73–74uC; IR
(film) 3226 (N-H str.), 2920, 2851 (C-H, str.), 1716, 1671 (C=O,
str.), 1468, 1375, 1278 cm21; 1H NMR (CDCl3, 600 MHz) d 5.73
(1H, brs, NH), 3.50 (1H, dd, 3J = 9.0, 3J = 6.0 COCHCO), 3.44
(1H, ddd, 2J = 9.0, 3J = 8.5, 3J = 5.5, CH2N), 3.34 (1H, ddd,
2J = 9.0, 3J = 9.0, 3J = 5.4, CH2N), 2.95 (1H, ddd,
2J = 17.4,
3J = 7.4, 3J = 7.5 CH2CH2CO), 2.57 (1H, ddd,
2J = 17.4,
3J = 7.2, 3J = 7.2 CH2CH2CO), 2.65 (1H, dddd,
2J = 11.0,
3J = 5.4, 3J = 9.0, 3J = 9.0, CH2CH2N), 2.17 (1H, dddd,
2J = 11.0,
3J = 8.5, 3J = 9.0, 3J = 5.5, CH2CH2N), 1.59 (2H, m,
CH2CH2CO), 1.23 (22H, m, C11H22), 0.88 (3H, t,
3J = 6.8,
CH3CH2);
13C NMR (CDCl3, 150 MHz) d 205.9 (CH2CO),
171.6 (CONH), 53.9 (COCHCO), 42.9 (CH2CO), 40.6 (CH2N),
32.1 (CH3CH2CH2), 29.8,29.2, 23.5 (CH2CH2CH2CO), 22.9
(CH2CH2CH2NH), 14.9 (CH3); MS(EI
+) m/z= 295 (M?+), HRMS
(EI) calculated for C18H33NO2 (M
?+) 295.2511, found 295.2554.
(2R, 5S)-2-(p-Fluorophenyl)-3-oxa-1-azabicyclo[3.3.0]octan-
8-one (4). A solution of 5-hydroxymethylpyrrolidine-2-one
(580 mg, 5 mmol) and p-fluorobenzaldehyde (810 mg, 6.5 mmol)
in toluene (20 mL) containing PPTS (30 mg) was heated at reflux for
13 h using a Dean-Stark water separator. After cooling, the solution
was diluted with EtOAc, washed with saturated NaHCO3 aqueous
solution, then brine, dried (MgSO4), and evaporated under reduced
pressure to give a brown oil. Chromatographic separation on silica gel
by elution with CHCl3 gave 4 as a pale yellow oil (586 mg, 53%): IR
(film) 2920, 2851 (C-H, str.), 1701 (C=O, str.), 1559, 1507, 1437
(aromatic C=C bend.) 1301, 1099, 821, 668 cm21; 1H NMR
(CDCl3, 200 MHz) d 7.34 (2H, dd,
3J=8.0, 4J=5.5, H-Ph), 6.95
(2H, dd, 3J=8.6, 4JH-F=8.6, H-Ph), 6.20 (1H, s, OCHPh), 4.15 (1H,
dd, 2J= 7.4, 3J=6.4, CH2O), 4.04 (1H, m, NCHCH2O), 3.40 (1H, t,
2J = 7.4, 3J = 7.6, CH2O), 2.74 (1H,
2J=17.4 3J= 9.6, 3J = 9.4,
CH2CO), 2.47 (1H, ddd,
2J=17.4, 3J=3.7, 3J=9.8, CH2CO), 2.31
(1H, dddd, 2J=20.2, 3J=3.7, 3J=7.6, 3J = 7.0, CH2CH2CHN), 1.87
(1H, dddd, 2J=20.2, 3J=4.7, 3J=9.4, 3J = 9.8, CH2CH2CHN);
13C
NMR (CDCl3, 50 MHz) d 178.2 (CON), 163.5 (1C, d,
1JC-F=244.4,
CF), 129.5 (2C, d, 3JC-F=8.2, CHCHCF), 115.4 (2C, d,
2JC-F= 21.5,
CHCF), 86.7 (OCHPh), 71.8 (CH2O), 58.9 (NCH), 33.6 (COCH2),
23.1 (COCH2CH2).
(2R, 5S)-2-(p-Fluorophenyl)-7-tetradecanoyl-3-oxa-1-azabicyclo
[3.3.0]octan-8-one (5). To a solution of protected lactam 4 (222 mg,
1 mmol) and HMPA (5 mL) in THF (15 mL), LiN(TMS)2 (1.0 M,
1.3 mL, 1.3 mmol) in THF was added at278uC. The reaction mixture
was stirred for 30 min, and then ethyl myristate (0.4 mL, 1.2 mmol) was
added. The solution was slowly warmed to room temperature. After 3 h,
the reaction mixture was quenched with saturated NH4Cl aqueous
solution, extracted with ether, and the extract was dried (Na2SO4), and
concentrated. The resulting product was purified by chromatography
(hexanes/EtOAc, 2:1) to give 5 as white crystals (233 mg, 53%)whichwas
formed as a mixture of two diastereomers: mp 60–62uC; IR (film) 2918,
2851 (C-H, str.), 1716, 1681 (C=O, str.), 1559, 1512 (aromatic C=C
bend.), 1401, 1240, 1035, 802 cm21; MS (EI+) m/z=431 (M?+), HRMS
(EI) calculated for C26H38NFO3 (M
?+) 43.2913, found 431.2914.
(5R)-5-(Hydroxymethyl)-3-tetradecanoylpyrrolidin-2-one
(6). A solution of protected lactam 5 (50 mg, 0.15 mmol) in
5 mL AcOH/THF/H2O (3:7:1) was warmed at 90uC for 3 h.
Benzene (30 mL) was added to the mixture and evaporated under
reduced pressure. Flash chromatography was performed (EtOAc/
CH3OH, 10:1) to yield 6 as white crystals (22 mg, 60%) of a
mixture of diastereomers: mp 73–76uC; IR(film) 3385 (NH str.),
3307 (OH, str.), 2920 (C-H, str.), 1699, 1653 (C=O, str.), 1457,
1119 cm21; MS (EI+) m/z= 325 (M?+), HRMS (EI) calculated for
C19H35NO3 (M
?+) 325.2617, found 325.2599.
Figure 1. Chemical structures of PMC analogs.
doi:10.1371/journal.pone.0056369.g001
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(2S, 5S, 7R)-7-Hydroxy-(4-fluorophenyl)-3-oxa-1-azabicyclo
[3.3.0]octan-8-one (7). Compound 6 (200 mg, 0.46 mmol) was
added to a suspension of CeCl3.7H2O (5.6 mg, 0.015 mmol) in 2 mL
i-PrOH. The suspension was mixed by bubbling air through it for 2 h
at room temperature. The reaction mixture was concentrated. Flash
chromatography was performed (CH2Cl2/EtOAc, 1:1) to yield 7 as a
colorless oil (120 mg, 57%): IR (film) 3384 (OH, str.), 1715, 1698
(C=O, str.), 1511, 1230, 1156 cm21; [a]D
23=20.050 (c=0.8 g/
100 mL, CH3OH);
1H NMR (DMSO-d6, 600 MHz) d 7.41 (2H, dd,
3J= 8.9, 4J=5.5, H-Ph), 7.23 (2H, dd, 3J= 8.9, 4JH-F=8.9, H-Ph),
6.62 (1H, s, OH), 6.11 (1H, s, H-Ph), 4.28 (1H, dd, 2J=8.1, 3J = 8.4,
CH2O), 4.01 (1H, dddd,
3J=6.8, 3J=7.0, 3J = 8.4, 3J = 6.0,
NCHCH2), 3.51 (1H, t,
2J = 8.4, 3J = 8.1, CH2O), 2.75 (1H, dd,
2J= 13.0, 3J = 6.8, CH2CHN), 2.69 (2H, dd,
2J=18.5, 3J = 7.2,
CH2CH2CO), 1.90 (1H, dd,
2J=13.0, 3J = 7.0, CH2CHN);
13C
NMR (DMSO-d6, 150 MHz) d 209.3 (CH2CO), 172.3 (CON),
162.2 (1JC-F=244.4, C-Ph), 134.7 (C-Ph), 128.3 (2C,
3JC-F=8.4, C-
Ph), 115.2 (2C, 2JC-F=21.7, C-Ph), 87.7 (C-OH), 85.6 (CH-Ph), 72.2
(CH2O), 54.6 (CH2CHN), 37.2 (CH2CHN), 36.2 (CH2CH2CO),
22.6 (CH2CH2CO), 22.05,31.25, 13.9 (CH3CH2); MS (EI+) m/
z=447 (M?+), HRMS (EI) calculated for C26H42FN2O4 [(M
?+NH4)+]
465.3129 found 465.3126.
(3S, 5R)-3-Hydroxy-5-(hydroxymethyl)-3-tetradecanoyl
pyrrolidin-2-one (8). A solution of compound 7 (60 mg,
0.13 mmol) in 5 mL AcOH/THF/H2O (3:7:1) was warmed at
90uC for 3 h. C6H6 (30 mL) was added to the mixture and
evaporated under reduced pressure. Flash chromatography was
performed (EtOAc/CH3OH, 10:1) to yield 8 as white crystals
(22 mg, 48%): mp 74–76uC; IR(film) 3300 (NH, str.), 3226 (OH,
str.), 2995, 2849 (C-H, str.), 1688, 1650 cm21 (C=O, str.);
[a]D
23 =24.25u (c = 0.04 g/100 mL, CH3OH); 1H NMR
(CD3OD, 600 MHz) d 3.81 (1H, dddd,
3J = 4.9, 3J = 5.4,
3J = 6.3, 3J = 7.9, CH2CHN), 3.62 (1H, dd,
2J = 11.1, 3J = 4.9,
CH2O), 3.53 (1H, dd,
2J = 11.1, 3J = 6.3, CH2O), 2.74 (2H, m,
CH2CH2CO), 2.38 (1H, dd,
2J = 14.1, 3J = 5.4, CH2CHN), 2.10
(1H, dd, 2J = 14.1, 3J = 7.9, CH2CHN), 1.56 (2H, m,
CH2CH2CO), 1.31 (3H, t,
3J = 7.0, CH3CH2);
13C NMR
(CD3OD, 150 MHz) d 212.2 (CO), 176.7 (CON), 84.5 (COH),
65.5 (CH2OH), 54.3 (CHN), 38.7 (CH2CO), 33.1,30.8, 24.3
(CH2CH2CO), 14.4 (CH3CH2); MS (EI
+) m/z= 341 (M?+),
HRMS (EI) calculated for C19H35NO4 (M
?+) 341.2617 found
341.2599.
PMC and analogs were dissolved in ethanol. McCoy’s 5A, FBS
and antibiotics were from Pan Biotech GmbH (Aidenbach,
Germany). Phosphatase inhibitor cocktail (PhosStop) and protease
inhibitor cocktail were obtained from Roche (F. Hoffman-La
Roche Ltd., Basel, Switzerland). Annexin V (FITC) was from
Alexis Biochemicals (Enzo Life Sciences, Inc. Farmingdale, USA).
Cleaved caspase-3, cleaved caspase-9, JNK, P-JNK, p38, P-p38,
Bcl-2, Bax, Bid, Bim and b-actin antibodies were purchased from
Cell Signaling Technology Inc. (Beverly, MA, USA). MAPK
inhibitors SP600125 and SB203580 were from Calbiochem (La
Jolla, CA, USA). Caspase inhibitors Z-VAD-FMK (general
caspase inhibitor), Z-DEVD-FMK (caspase-3 inhibitor), Z-
LEHD-FMK (caspase-9 inhibitor), and Z-IETD-FMK (caspase-8
inhibitor) were purchased from BD Biosciences (San Jose, CA,
USA). Tris, glycine and Tween-20 were from Molekula Ltd
(Shaftesbury, UK). All other chemicals were obtained from Sigma
(Darmstadt, Germany).
MTT Cell Viability Asssay
Cell viability upon exposure to PMC analogs was determined
using an MTT (dimethyl thiazolyl diphenyl tetrazolium) assay kit
(Roche, Mannheim, Germany) according to the manufacturer’s
protocol. Briefly, HCT116 wt cells in 96-well plates were treated
as indicated, and 10 ml of MTT labeling reagent was added to
each well, after which the plates were incubated for 4 hours. The
cells were then incubated in 100 ml of the solubilization solution
for 12 hours, and the absorbance was measured with a microtiter
plate reader (Bio-Rad, CA, USA) at a test wavelength of 550 nm
and a reference wavelength of 650 nm. Percent viability was
calculated as (OD of drug-treated sample/control OD)6 100.
Flow Cytometry
Cell death was determined by an Annexin-V affinity assay. Wt,
p532/2, and Bax 2/2 HCT116 cells seeded in 12-well plates
were transfected/treated as indicated, transferred to flow cytom-
etry tubes and cells were harvested by centrifugation at 300 g for 5
minutes. Then the cells were resuspended in 1 ml of cold PBS and
centrifuged again at 300 g for 5 minutes. After removal of
supernatant, the cells were incubated in Annexin V buffer
(140 mM HEPES, 10 mM NaCl, 2,5 mM CaCl2, pH:7.4)
containing 1% (v/v) Annexin V (FITC) for 15 minutes in the
dark. Cells were analyzed by FACS (FACSCanto, Becton
Dickinson).
Protein Extraction and Immunoblotting
Cells were treated as indicated and harvested by centrifugation
at 300 g for 30 seconds. Following resuspension in 1 ml of ice-cold
PBS and transfer to 1.5-ml microfuge tubes, cells were spun at
13200 rpm for 30 seconds. The pellet was lysed by incubation for
30 minutes in 200 ml of cold cell lysis buffer containing 50 mM
Tris-HCl (pH:8.0), 150 mM NaCl, 1 mM phenylmethanesulfonyl
fluoride, protease and phosphatase inhibitor cocktails, and
Nonidet P-40 1% (v/v). After centrifugation at 13200 rpm for
10 minutes, supernatant containing the total protein extract was
removed and stored at 280uC. Protein concentrations were
determined by DC protein assay (Bio-Rad, Munich, Germany).
Proteins (30 mg) were mixed with loading buffer (4% SDS, 20%
glycerol, 10% 2-mercaptoethanol, 0,004% bromophenol blue,
0,125 M Tris-HCl pH:6,8) and separated on 10–15% SDS-PAGE
and blotted onto PVDF membranes. The membranes were
blocked with 5% blocking reagent (ECL Advance, Amersham
Pharmacia Biotech, Freiburg, Germany) in PBS-Tween20 and
incubated with appropriate primary and HRP-conjugated sec-
ondary antibodies (Amersham Pharmacia Biotech, Freiburg,
Germany) in 5% blocking reagent. After required washes with
PBS-Tween20, proteins were finally analyzed using an enhanced
chemiluminescence detection system (ECL Advance, Amersham
Pharmacia Biotech, Freiburg, Germany) and exposed to Hyper-
film-ECL (Amersham Pharmacia Biotech, Freiburg, Germany).
Transfections
HCT116 wt cells were transfected with Bcl-2 and Bim
expression plasmids (Addgene Inc., Cambridge, MA, USA) using
FuGene 6 transfection reagent (Roche, F. Hoffman-La Roche
Ltd., Basel, Switzerland) according to the manufacturer’s protocol.
Total protein extraction was performed after 24 hours following
completion of transfection procedure for confirmation of ectopic
expression. Plasmid-transfected cells were treated with PMC-A as
indicated and analyzed by flow cytometry after 24 hours.
Statistical Analysis
All the illustrated results represent one of at least three
independent experiments with similar outcomes. All numerical
data are presented as as means 6 SD. Statistical significance of
responsive differences among differentially treated or differentially
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transfected cell populations were assessed with unpaired or paired
student’s t-test, respectively. Values of P,0.05 and P,0.01 are
marked as * or **, respectively.
Results
PMC-A Proves More Cytotoxic Compared to Its Precursor
PMC and Several Analogs against HCT116 Cells
PMC was previously shown to selectively damage vascular
endothelial cells in in vitro functional studies on rat aorta and dog
arteries [1,21,22]. PMC and analogs were also demonstrated to
cause cell death in cultured bovine vascular endothelial and Jurkat
T leukemia cells [1,2]. In our study, we initially investigated the
previously reported natural products PMC and PMC-A [20], and
then synthesized several analogs to explore structure-function
relationships (Fig. 1). Thus, PMC-C was prepared from commer-
cial N-vinylpyrrolidinone (1) by formation of the enolate, then
acylation with ethyl myristate to give 2. The vinyl protecting group
was then removed with aqueous acid, giving PMC-C (3) as a
racemic mixture at the readily epimerized stereocentre (Fig. 2).
For analogs PMC-D and –F, commercial (R)-5-hydroxymethyl-
pyrrolidine-2-one was converted to the protected derivative 4,
using a literature procedure [23], then deprotonated and acylated
with ethyl myristate, giving 5. Deprotection then afforded PMC-D
(6). Alternatively, hydroxylation of 5 with oxygen and cerium
chloride as catalyst according to the method of Christoffers [24]
gave 7 which was then deprotected to yield PMC-F (8). Use of the
p-fluorophenyl protecting group conveniently resulted in essen-
tially completely stereoselective hydroxylation, whereas other
substituents on the benzene ring gave mixtures. The stereochem-
istry of 8 was established by X-ray crystallography, which revealed
that the hydroxy group was trans to the hydroxymethyl substituent,
as opposed to the cis relationship in pramanicin. It was therefore of
interest to establish whether this hydroxy group and its stereo-
chemistry are important for activity, and thus we included this
compound in the test panel.
We then performed a 24 hour cytotoxicity assay to search for
the most potent analog against HCT116 cells. MTT reduction test
which indirectly determines cell viability/proliferation by moni-
toring metabolic activity, revealed that 100 mM PMC caused
approximately 8% decrease in cell viability (Fig. 3). However,
PMC-A which possesses a C=C double bond instead of an epoxy
group in its side chain, decreased the cell viability by almost 70%
compared to the untreated control. Notably, analogs PMC-C, -E
and –F all retained significant activity, indicating that an acylated
pyrrolidinone (as in PMC-C), at most, is the key pharmacophore
and that many of the substituents (epoxide, diene, C-5 hydro-
xymethyl group, and the C-3 and C-4 alcohol groups) are non-
essential but enhance activity.
PMC-A Induces Cell Death through Induction of Intrinsic
Apoptotic Pathway
In vitro effective doses of the potent PMC analog PMC-A (25–
100 mM) caused cell death in a dose-dependent manner among all
three HCT116 colon cancer cell lines (wt, p532/2, and Bax2/2)
as indicated by increased Annexin-V affinities in cell populations
(Fig. 4A). In order to analyze cell death and determine the optimum
dose to use in a 24 hour time scale, we applied flow cytometry
following Annexin-V staining of cells exposed to four physiologically
relevant PMC-A concentrations. Cell death induction was evident
for all doses in all cell lines and increased dose-dependently. Given
that, more than 50% of the wt cells were dead after 24 hour
exposure to 100 mM PMC-A, we conducted the rest of the
immunoblotting experiments using 50 mM dose at which approx-
imately 70% of cells remained alive at 24 hours post-exposure.
Figure 2. Synthesis of PMC analogs.
doi:10.1371/journal.pone.0056369.g002
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Not surprisingly considering the wide-range modulatory activity
of the tumor suppressor p53 on cell fate, lack of p53 expression
proved to render HCT116 cells more resistant to PMC-A induced
apoptosis at doses higher than 25 mM. Bax 2/2 cells on the other
hand, were significantly protected from PMC-A induced cell death
at all doses to a greater extent than p532/2 cells.
Critical involvement of the intrinsic apoptotic pathway that was
evident by protection of Bax 2/2 HCT116 cells from PMC-A
induced apoptosis, was further confirmed by detection of relevant
caspase activities and analysis of pharmacological inhibition of
these activities. We investigated the caspase activity by immuno-
blotting using antibodies specific to cleaved (active) forms.
Caspases 9 and 3 were both activated at early hours of PMC-A
treatment and these activities were sustained during a 24 hours
post-exposure period in both wt and p532/2 cells (Fig. 4B).
Inhibition of caspase-9, -3, or all caspases with specific chemical
inhibitors significantly protected the HCT116 cells from PMC-A
triggered apoptosis (Fig. 4C).
Both Stress-related MAPKs JNK and p38 are Involved in
PMC-A Induced Apoptosis: p38 MAPK Activation Appears
to Be Critical
PMC was previously shown to induce both stress-activated
MAPKs p38 and JNK, and pharmacological inhibition of these
MAPKs had proved to protect Jurkat T leukemia cells from PMC
induced apoptosis [2]. Similarly, we investigated the activities of
JNK and p38 by immunoblotting using antibodies directed against
phosphorylated active forms of these MAPKs. Our analyses in
HCT116 cells revealed that PMC-A induces early activation of
both JNK and p38 as indicated by increase in cellular levels of P-
JNK and P-p38 (Fig. 5A). Activities of both kinases were sustained
up to almost 24 hours in both wt and p532/2 cells. Moreover,
pretreatment of the cells with the specific pharmacological
inhibitor of p38 SB203580, but not the JNK inhibitor
SP600125, prior to PMC-A exposure significantly protected the
cells from apoptosis (Fig. 5B).
Bcl-2 Dowregulation and Bim Activaton are Critical
Events to Mediate PMC-A Induced Apoptosis
Analysis of cellular protein levels during the first 24 hours of
PMC-A exposure indicated substantial changes in cellular pro-
and antiapoptotic Bcl-2 proteins (Fig. 6). Early elevation of
proapoptotic Bim and Bax was followed by depletion of
antiapoptotic Bcl-2, and cleavage of proapoptotic Bid in response
to PMC-A exposure in both wt and p532/2 HCT116 cells. Bim
and Bax upregulation appeared to be initiated before 2 hours post-
exposure and increased cellular Bim/Bax levels were sustained
throughout the 24 hours following PMC-A treatment. Relevantly,
Bax is known to be post-translationally activated by so-called
activator Bcl-2 proteins Bim, Bid, and Puma to initiate OMM
permeabilization as well as potentially being a target of
transcription factors such as p53, SP1 (specificity protein 1),
Nur77 family of nuclear receptors, and NF-kB (nuclear factor-kB)
at the gene level for transactivation/-repression [5,7,25–32]. Bax/
Bim upregulation was followed by Bcl-2 downregulation beginning
from 8 hours post PMC-A exposure and culminating at 24 hours
post-exposure. This dramatic downregulation was preceded by a
transient slight increase in cellular Bcl-2 in the early hours of
exposure in both wt and p532/2 cell lines. Truncation of Bid
which may mark secondary involvement of the extrinsic apoptotic
pathway took place as a late response to PMC-A in both cell lines.
However, it should be noted that Bid cleavage was relatively
delayed in p532/2 cells as cleavage product was not visible until
24 hours post-exposure.
The relatively late decrease in Bcl-2 expression was dose-
dependent and confirmed to take place at the transcriptional level
by quantitative real-time polymerase chain reaction (qRT-PCR)
analysis (Fig. 7A, B). Bcl-2 expression was decreased in PMC-A-
treated cells to almost one fifth of the expression in untreated
control cells. Moreover, interrogation of HCT116 cells that were
transiently transfected with the human Bcl-2 gene revealed that
this regulation was critical in response to PMC-A. Annexin-V
binding analysis shows that cells that ectopically express Bcl-2 were
significantly more resistant to PMC-A induced apoptosis (Fig. 7C).
Finally, we forced HCT116 wt cells to express BH3-only
proapoptotic Bim which displayed early cellular increase in
response to PMC-A (Fig. 6). Use of BimL expression vector was
exploited to interrogate whether this upregulation is a contributing
factor to apototic effects of PMC-A (Fig. 8). Flow cytometry
analysis showed that it is possible to amplify the apoptotic response
to PMC-A by ectopic Bim expression.
Discussion
An elaborate network of pathways is required to tightly control
apoptotic events in mammalian cells. Failure of surveillance/
maintanence over cell fate decision could result in malignant
transformation. Evasion from apoptosis as a hallmark of cancerous
cells may involve dysregulation of Bcl-2 family proteins as evidence
indicates that a wide variety of solid and hematopoietic tumors rely
on elevated antiapoptotic Bcl-2 protein expression for survival
[33–36]. In this view, inspection of cellular levels and activation
statuses of pro- and antiapoptotic Bcl-2 proteins may provide
valuable clues about anticancer drug action.As a result, interest in
Figure 3. PMC-A is the most cytotoxic compound among PMC
analogs. Viabilities of HCT116 cells were analyzed by MTT assay
following 24 h treatment with 100 mM of each PMC analog. Wild-type
HCT116 cells were assayed colorimetrically following 24 h treatment
with PMC analogs. Average absorption values relative to untreated
control are displayed after multiplication with 100. The results from at
least 3 independent experiments were shown as means 6 SD.
Difference of mean values between treated and untreated samples
were tested using unpaired student’s t-test; **P,0.01. Control cells
were treated with solvent only. All tested analogs except the precursor
PMC led to significant loss of viability/proliferation while PMC-A and -F
proved most cytotoxic to cells.
doi:10.1371/journal.pone.0056369.g003
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Figure 4. PMC-A induces dose-dependent cell death by activating intrinsic apoptotic pathway. HCT116 wt, p532/2 and Bax 2/2 cells
were collected and analyzed by flow cytometry following 24 h treatment with indicated doses of PMC-A (A). Difference of mean values between
treated and untreated cells of the same cell line were tested using unpaired student’s t-test. PMC-A caused significant dose-dependent cell death in
all cell lines. Mean values of PMC-A-treated p532/2 or Bax 2/2 cells against those of PMC-A-treated wt cells were tested using paired student’s t-
test; *P,0.05, **P,0.01. Lack of Bax expression significantly protected the cells from PMC-A induced cell death at doses of 50, 75, and 100 mM. Wild
type and p532/2 HCT116 cells were treated with 50 mM PMC-A and were harvested at indicated time points, lysed and immunoblotted with anti-
cleaved caspase-3, anti-caspase-9, and anti-b-actin antibodies (B). Mitochondria mediated (intrinsic) apoptotic pathway was activated as shown by
cleavage of caspase-9 and caspase-3 in both cell types following the treatment. HCT116 wt cells that were pretreated with specific caspase inhibitors
Z-LEHD-FMK, Z-DEVD-FMK, or Z-VAD-FMK were collected and analyzed by flow cytometry following 24 h 50 mM PMC-A treatment as well as
unpretreated/untreated cells (C). Difference of mean values between pretreated and unpretreated cells were tested using unpaired student’s t-test;
**P,0.01. Pharmacological inhibition of caspase-9, -3 and all caspases at once resulted in protection from PMC-A induced cell death. The results from
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Bcl-2 family regulation by putative or established chemotherape-
tics has been increasing. The materialisation of the idea of
interfering with expressions/activities of specific Bcl-2 targets in
cancerous cells challenges us to develop a complete understanding
of the behaviour of Bcl-2 proteins in response to different
anticancer agents in various neoplasms. Although use of antisense
oligonucleotides has been challenged with efficient drug delivery
issues in clinical trials, significant achievements of non-peptidic
small molecule inhibitors (SMI) of antiapoptotic Bcl-2 proteins are
ensuring the acceleration of efforts to design Bcl-2 manipulation-
based therapeutic approaches [37–44].
This study is the second investigation to implicate PMC analogs
in anticancer activity with the aim of elucidating the basic
mechanism of the induced apoptosis [2]. Although having being
studied in normal vascular endothelial and leukemic T cells,
pramanicin analogs was yet to be tested for anticancer action
against solid cancer models. High mutation rates stemming from
their deficiency in mismatch repair and the resultant aggressive
behaviour associated with reported resistance against genotoxic
chemotherapeutics make HCT116 epithelial colon cancer cell line
an appropriate solid cancer model [45]. Cytotoxicity analysis on
HCT116 cells demonstrated the potent growth inhibitory action of
PMC-A as opposed to little cytotoxicity of PMC at relevant in vitro
doses (Fig. 3). PMC-A was further confirmed to induce cell death
(Fig. 4A). Early post-exposure activations of apical caspase-9 and
subsequent executioner caspase-3 together with abrogation of
at least 3 independent experiments were shown as means 6 SD for Panel A and C. Western results from one of three independent experiments are
shown. b-actin was used as loading control. Control cells were treated with solvent only.
doi:10.1371/journal.pone.0056369.g004
Figure 5. Activation of p38 is critical in PMC-A induced apoptosis. Wild type and p532/2 HCT116s were treated with 50 mM PMC-A and
harvested at indicated time points, lysed and immunoblotted with anti-P-JNK, anti-JNK, anti-P-p38, anti-p38 and anti-b-actin antibodies (A). b-actin
was used as loading control. Results from one of three independent experiments are shown. JNK pathway was activated at 8 h and remained active
up to 24 h in both cell types while p38 was activated earlier at 2 h and maintained its activity up to 24 h in wt and up to 12 h in p532/2 cells.
HCT116 wt cells that were pretreated with SB203580 or SP600125 were collected and analyzed by flow cytometry following 24 h 50 mM PMC-A
treatment together with unpretreated/untreated cells (B). The results from at least 3 independent experiments were shown as means 6 SD.
Difference of mean values between pretreated and unpretreated cells were tested using unpaired student’s t-test; **P,0.01. Pharmacological
inhibition of p38 resulted in protection from PMC-A induced cell death while JNK inhibition did not cause any significant change in cell death
response. Control cells were treated with solvent only.
doi:10.1371/journal.pone.0056369.g005
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PMC-A induced cell death upon pretreatment with pharmaco-
logical caspase-3 and general caspase inhibitors clearly indicate the
apoptotic nature of the induced cell death (Fig. 4B, C).
Roughly inspecting the time course of Bcl-2-modulatory events
showed early Bim and Bax upregulation followed by Bcl-2
downregulation and late truncation of Bid. Forced expression
analyses of Bim and Bcl-2 ended up with identification of Bcl-2
downregulation and Bim upregulation as important mediators of
PMC-A triggered apoptosis. Ectopic expression of antiapoptotic
Bcl-2 prevented HCT116 cells from cell death to a large extent
(Fig. 7C). On the other hand, although apoptotic promotion was
significant, ectopic expression of proapoptotic Bim appeared to be
less effective compared to Bcl-2 in modulating apoptosis. Given
the fact that the elevation of cellular Bim and Bax precedes Bcl-2
downregulation, roles of these earlier events should not be
underestimated. Bim, as an activator Bcl-2 protein, is capable of
direct Bax/Bak activation upon reversible binding and known to
potently antagonize all prosurvival Bcl-2 proteins which sequester
Bax/Bak under normal circumstances [5,6]. Bim may have at least
3 isoforms expressed as alternative splicing variants in mammalian
cells [6,46,47]. Other than BimL which was ectopically expressed
in HCT116 cells in this study, two other isoforms BimS and
BimEL are also known to mediate apoptosis in a similar fashion to
BimL [48,49]. Immunoblotting results show that BimS is also
upregulated with a similar time pattern in response to PMC-A and
may also have additive roles in mediating PMC-A induced
apoptosis in HCT116 cells (Fig. 6).
The Bcl-2 family of proteins were demonstrated to be regulated
at the transcriptional level via transactivation or -repression
through transcription factors including Mef2, Nur77, AP1, AP2,
SP1, Myc/Max, Stat1, p53 and NF-kB [7,10,17,26,30,50–60]. In
addition, post-translational modifications such as phosphorylation,
cleavage and proteasome mediated degradation were shown to
take place in different cellular contexts [49,61–63]. The time
course of Bcl-2 downregulation roughly marks 8 hours post-
exposure as the start point of this regulation (Fig. 6). Since caspase-
9 activation precedes Bcl-2 downregulation, Bcl-2 depletion may
not be the first event to lead OMM permeabilization, but
apparently plays a substantial role in amplification of the apoptotic
response. In this view, early upregulation of Bim and Bax appear
to initiate caspase cascade activation through OMM permeabili-
zation. Further investigation of PMC-A induced Bcl-2 downreg-
ulation by qRT-PCR indicated that expression of Bcl-2 was
significantly repressed at the transcriptional level (Fig. 7B).
Investigation of the roles of stress-activated kinases revealed that
pretreatment with specific p38 pharmacological inhibitor proved
to abrogate PMC-A mediated Bcl-2 downregulation while JNK
inhibition did not affect the induced modulations on Bcl-2, Bim or
Bax (Fig. S1). Among the transcription factors, NF-kB, SP1, p53
and AP-2 (activating protein-2) which all were previously shown to
be activated by p38 kinase activity in various cellular scenarios
were implicated in direct transcriptional regulation of Bcl-2 in
stressed cancer cells [17,54,55,60,64–67]. While NF-kB and SP1
are generally implicated in transactivation of the BCL-2 gene, p53
and AP-2a were demonstrated to be responsible for transcriptional
repression of Bcl-2. Relevant to our analysis, knockdown studies
and further interrogation of nuclear import and activation statuses
of aforementioned apoptotic modulator transcription factors,
especially AP-2a, could provide further insights into the anticancer
mechanism of action of PMC analogs at the nuclear level.
Bid cleavage is a well-known apoptotic event linking the
extrinsic apoptotic pathway to the intrinsic apoptotic route to
amplify the apoptotic signal. Procaspase-8 is activated through a
sequence of events including recruitment of adaptor molecules,
homooligomerization and autocatalytic cleavage upon engage-
ment of death receptors on the cell surface [4]. Active caspase-8
which stands at the apex of the extrinsic apoptotic route
contributes to procaspase-3 processing and synchronously acti-
vates BH3-only protein Bid by cleavage to initiate OMM
permeabilization. Our analysis shows that Bid cleavage took place
at fairly late hours following PMC-A treatment in HCT116 cells
(Fig. 6). Late involvement of Bid cleavage and failure of caspase-8
inhibitor pretreatment to blunt PMC-A mediated apoptosis, makes
us speculate that the extrinsic apoptotic pathway is activated
secondary to the intrinsic apoptotic route (Fig. S2). Indeed, rather
than being driven by a death receptor binding, such a secondary
involvement of the extrinsic apoptotic route could have taken
place as a result of cleavage of procaspase-8 by caspase-3 which
was already activated by the intrinsic apoptotic pathway at the
very beginning of PMC-A exposure [68].
Figure 6. Bcl-2 downregulation and Bid processing follows Bax/Bim elevation in a p53-independent fashion in response to PMC-A.
Wild-type and p532/2 HCT116 cells were treated with 50 mM PMC-A, collected at indicated time points, lysed and immunoblotted using anti-Bax,
anti-Bid, anti-Bim, anti-Bcl-2 and anti-b-actin antibodies. b-actin was used as loading control. Results from one of three independent experiments are
shown. Cellular proapoptotic Bax levels were upregulated as early as 2 h and sustained up to 24 h similar to the increase in L and S isoforms of
another proapoptotic protein Bim in both wild type and p532/2 cells. Antiapoptotic Bcl-2 downregulation started at 8 h and culminated at 24 h
post-exposure while proapoptotic Bid truncation took place in the late hours of treatment in both cell lines.
doi:10.1371/journal.pone.0056369.g006
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Although it would be tempting to argue that PMC-A mediated
Bcl-2 family regulation is related with tumor suppressor p53
signaling, all the above mentioned modulations were also
apparent, at least at the protein level, in p53-null cells. However,
it should be noted that Bid cleavage was visible only at 24 h post-
exposure in cells lacking p53 expression while in wt cells the
cleavage was evident as early as 8 hours after PMC-A treatment.
This quicker response in the involvement of the extrinsic apoptotic
pathway in wt cells could possibly be related with p53-dependent
death receptor gene transactivation [69]. Although Bax is known
to be a direct target of p53 transcription factor, the time course of
cellular Bax elevation was similar in both wt and p532/2 cells
upon PMC-A treatment (Fig. 6). Similarly, both Bim upregulation
and Bcl-2 downregulation followed almost identical patterns
independently of p53 expression in cells.
In brief, this study demostrates that PMC analogs display
chemotherapeutic potential in addition to their previously shown
potential against in vitro hematopoietic malignancy models. We
define a p53-independent modulation of the Bcl-2 family of
proteins as the mediator of PMC-A induced apoptosis. PMC-A
rapidly induces the intrinsic apoptotic pathway through upregula-
tion of Bax and Bim which is followed by a dramatic Bcl-2
downregulation and Bid truncation. The central role of the
intrinsic apoptotic pathway was further confirmed by the
Figure 7. Transcriptional downregulation of Bcl-2 is critical to mediate PMC-A induced apoptosis. Wild type HCT116 cells were treated
with indicated concentrations of PMC-A and harvested at 24 h post-exposure, lysed and immunoblotted with anti-Bcl-2 and anti-b-actin antibodies
(A). b-actin was used as loading control. Downregulation of cellular Bcl-2 was amplified by increasing PMC-A dose. HCT116 wt cells were treated with
indicated PMC-A concentrations, harvested after 24 h for total RNA extraction, cDNA synthesis and qRT-PCR analysis (B). A marginal (,5-fold)
decrease in Bcl-2 transcription was evident upon PMC-A treatment (p,0,01). HCT116 wt cells were transiently transfected with expression plasmids
either carrying human Bcl-2 gene or mock vector only (C). Transfected cells were treated with 50 mM PMC-A before collection and flow cytometry
analysis. The results from at least 3 independent experiments were shown as means 6 SD. Difference of mean values between mock and Bcl-2-
transfected cells were tested using paired student’s t-test; **P,0.01. Analysis indicates that ectopic Bcl-2 expression renders the cells more resistant
against PMC-A induced apoptosis. Bcl-2 expression statuses of mock- and Bcl-2-transfected cells prior to PMC-A treatment are displayed as
immunoblotting results obtained from cells that were harvested, lysed and immunoblotted with anti-Bcl-2 antibody (C). Results from one of three
independent experiments are shown in immunoblotting results.
doi:10.1371/journal.pone.0056369.g007
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protective effects of Bcl-2 overexpression and caspase-9 inhibition
prior to PMC-A treatment. In addition to shedding light upon the
apoptotic action mechanism of PMC-A, these results could also
prove invaluable for tailoring therapeutic approaches against solid
cancers. By revealing Bcl-2 downregulation as the basic mecha-
nism of action of PMC-A to promote apoptosis, this study also
provides supporting evidence for justification of clinical trials based
on antisense/SMI strategies directed against Bcl-2 protein in
various cancers.
Supporting Information
Figure S1 Pre-treatment with specific p38 inhibitor
reverses PMC-A mediated Bcl-2 downregulation.
HCT116 wt cells were pretreated with indicated concentrations
of JNK (SP600125), p38 MAPK (SB203580) or IKK inhibitors for
30 min, treated with 50 mM PMC-A, collected at 4 h (Bax/Bim)
or 24 h (Bcl-2), lysed and immunoblotted using anti-Bax, anti-
Bim, anti-Bcl-2 and anti-b-actin antibodies. b-actin was used as
loading control. Results from one of three independent experi-
ments are shown. PMC-A induced depletion of cellular Bcl-2 was
restored upon pharmacological inhibition of p38MAPK in a dose-
dependent manner. PMC-A induced Bim/Bax elevation was not
affected with any of the three inhibitors used.
(PDF)
Figure S2 Pre-treatment with specific caspase-8 inhib-
itor does not cause significant protection from PMC-A
induced apoptosis. HCT116 wt cells that were pretreated with
10 mM. Z-IETD-FMK were collected and analyzed by flow
cytometry following 24 h 50 mM PMC-A treatment together with
unpretreated/untreated cells. The results from at least 3
independent experiments were shown as means 6 SD. Difference
of mean values between pretreated and unpretreated cells were
tested using unpaired student’s t-test. Z-IETD-FMK pretreatment
did not cause a significant protection from PMC-A induced
apoptosis at P = 0.05 level. Control cells were treated by solvent
only.
(PDF)
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